uPath HER2 (4B5) image analysis for breast cancer
Histopathology
breast
FDA-cleared digital pathology algorithm for quantification of HER2 (4B5) immunohistochemistry on breast cancer tissue sections.
Regulatory
| Regulatory status | 510(k) cleared |
| FDA submission pathway | 510(k) |
| FDA decision date | 2007-01-10 |
| FDA 510(k) number | K061613 |
| CE marked | Yes |
Validation summary
Validation summary not yet populated. This entry currently lists only the regulatory pathway and headline citation; structured cohort and endpoint data are queued for v0.3.
| Study design | — |
| Cohort size | — |
| Number of validation sites | — |
| Site geography | — |
| Comparator | — |
| Primary endpoint | — |
| Primary result | — |
| External validation | — |
| Peer-reviewed | — |
| FDA decision summary | — |
Deployment
| Available | Yes |
Sources
- https://diagnostics.roche.com/us/en/products/instruments/upath-enterprise-software.html · company · 2026-04-20
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm · fda_db · 2026-04-20
How to cite this entry
Elbakri A. OncologyAI Registry: uPath HER2 (4B5) image analysis for breast cancer. Available at: https://oncologyairegistry.org/tools/roche-upath-her2-breast.html. Accessed [date].